CRF Health
announced new medical device integrations to support both spirometers and glucometers used in Phase I-IV respiratory and diabetes clinical trials. CRF Health’s eDiary TrialMax® platform now integrates with Entra Health Systems’ Bluetooth-enabled MyGlucoHealth Wireless Meter and Vitalograph’s Asma-1 electronic Peak Flow Meter.
The wireless integration of our eDiaries with these medical devices results in more accurate data by removing the need for manual transcription of the data values. The date and time stamp of the reading and the device serial number are also transferred, providing evidence of the timeliness of the data and an attributable source. Once the eDiary receives the values from the glucometer or PEF meter, the values can automatically be sent to the ePRO database for review by the site personnel or study team. This allows very close to real-time monitoring of the subject’s status and permits timely intervention for safety or compliance concerns.
Benefits for clinical trial Sponsors include:
· Near real time access to all patient-generated data
· Defensible data that meets the FDA’s ALCOA standard
· Ease of use – no wires or cradles to connect
· High compliance to protocol (reminder alerts)
· No data transcription errors
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.